RhumbLine Advisers’s Abeona Therapeutics ABEO Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $351K | Buy |
56,751
+904
| +2% | +$4.96K | ﹤0.01% | 2973 |
|
|
2026
Q1 | $250K | Sell |
55,847
-84
| -0.2% | -$420 | ﹤0.01% | 3009 |
|
|
2025
Q4 | $295K | Sell |
55,931
-7,742
| -12% | -$39K | ﹤0.01% | 2981 |
|
|
2025
Q3 | $336K | Sell |
63,673
-3,832
| -6% | -$24.3K | ﹤0.01% | 2918 |
|
|
2025
Q2 | $383K | Buy |
67,505
+65,651
| +3,541% | +$374K | ﹤0.01% | 2849 |
|
|
2025
Q1 | $8.82K | Hold |
1,854
| – | – | ﹤0.01% | 3849 |
|
|
2024
Q4 | $10.3K | Hold |
1,854
| – | – | ﹤0.01% | 3880 |
|
|
2024
Q3 | $11.7K | Buy |
1,854
+1,800
| +3,333% | +$9.4K | ﹤0.01% | 3871 |
|
|
2024
Q2 | $228 | Sell |
54
-4
| -7% | -$20 | ﹤0.01% | 4317 |
|
|
2024
Q1 | $420 | Hold |
58
| – | – | ﹤0.01% | 4195 |
|
|
2023
Q4 | $290 | Hold |
58
| – | – | ﹤0.01% | 4222 |
|
|
2023
Q3 | $243 | Hold |
58
| – | – | ﹤0.01% | 4262 |
|
|
2023
Q2 | $233 | Buy |
+58
| New | +$203 | ﹤0.01% | 4352 |
|
|
2021
Q2 | – | Sell |
-3,595
| Closed | -$169K | – | 2981 |
|
|
2021
Q1 | $169K | Hold |
3,595
| – | – | ﹤0.01% | 2866 |
|
|
2020
Q4 | $141K | Buy |
3,595
+612
| +21% | +$20.8K | ﹤0.01% | 2910 |
|
|
2020
Q3 | $76K | Sell |
2,983
-573
| -16% | -$36.1K | ﹤0.01% | 2914 |
|
|
2020
Q2 | $259K | Buy |
3,556
+705
| +25% | +$48.7K | ﹤0.01% | 2644 |
|
|
2020
Q1 | $150K | Buy |
2,851
+750
| +36% | +$50.1K | ﹤0.01% | 2674 |
|
|
2019
Q4 | $172K | Buy |
2,101
+67
| +3% | +$4.73K | ﹤0.01% | 2786 |
|
|
2019
Q3 | $115K | Buy |
2,034
+168
| +9% | +$12.6K | ﹤0.01% | 2862 |
|
|
2019
Q2 | $223K | Buy |
1,866
+243
| +15% | +$40.7K | ﹤0.01% | 2745 |
|
|
2019
Q1 | $299K | Sell |
1,623
-43
| -3% | -$7.69K | ﹤0.01% | 2555 |
|
|
2018
Q4 | $297K | Buy |
1,666
+532
| +47% | +$116K | ﹤0.01% | 2548 |
|
|
2018
Q3 | $363K | Sell |
1,134
-56
| -5% | -$19.9K | ﹤0.01% | 2419 |
|
|
2018
Q2 | $476K | Buy |
1,190
+70
| +6% | +$30.6K | ﹤0.01% | 2326 |
|
|
2018
Q1 | $402K | Buy |
1,120
+53
| +5% | +$19.7K | ﹤0.01% | 2298 |
|
|
2017
Q4 | $423K | Sell |
1,067
-119
| -10% | -$49.2K | ﹤0.01% | 2304 |
|
|
2017
Q3 | $505K | Buy |
1,186
+1
| +0.1% | +$269 | ﹤0.01% | 2301 |
|
|
2017
Q2 | $190K | Buy |
+1,185
| New | +$162K | ﹤0.01% | 2778 |
|
|
2016
Q2 | – | Sell |
-491
| Closed | -$31K | – | 2983 |
|
|
2016
Q1 | $31K | Hold |
491
| – | – | ﹤0.01% | 2976 |
|
|
2015
Q4 | $41K | Buy |
+491
| New | +$49.2K | ﹤0.01% | 3008 |
|
Other funds holding ABEO
NCM
CCC
ACM
OIA
AIC
KCM
RhumbLine Advisers's ABEO Position: Q2 2026 in Review
RhumbLine Advisers increased its Abeona Therapeutics (ABEO) stake by 1.6% in Q2 2026, buying an estimated $4.96K and bringing the position to 56,751 shares worth $351K. The position accounts for ﹤0.01% of the portfolio, ranked #2973.
RhumbLine Advisers first reported a position in ABEO in Q4 2015 and has held it in 31 quarters since. The position peaked at $505K in Q3 2017. 126 funds tracked by Wall St. Rank hold ABEO as of Q2 2026.
- RhumbLine Advisers held 56,751 shares of Abeona Therapeutics worth $351K as of Q2 2026.
- RhumbLine Advisers bought 904 Abeona Therapeutics shares in Q2 2026, an estimated $4.96K.
- Abeona Therapeutics made up ﹤0.01% of RhumbLine Advisers's portfolio in Q2 2026, its #2973 holding.
- RhumbLine Advisers first reported a position in Abeona Therapeutics in Q4 2015 and has held it in 31 quarters since.
- RhumbLine Advisers's Abeona Therapeutics position peaked at $505K in Q3 2017.
- 126 funds tracked by Wall St. Rank held Abeona Therapeutics as of Q2 2026.
Based on RhumbLine Advisers's 13F filing for Q2 2026, filed 12 Aug 2026.